|Organisation name||Function||Country||Website link||ECCP link|
Oslo Cancer Cluster SA
SMART INNOVATION OSTFOLD AS
Cluster Individualisierte Immunintervention (CI3) e.V.
intelligent views gmbh
NETSYNO Software GmbH
ONCOTYROL-CENTER FOR PERSONALIZED CANCER MEDICINE GMBH
BUSINESS UPPER AUSTRIA - OO WIRTSCHAFTSAGENTUR GMBH
Precision medicine “… is one of the biggest opportunities for breakthroughs in medicine that we have ever seen” (President Obama, Jan 2015) and is one of the emerging industries with high growth and innovation potential identified by the EU Commission (cf. http://www.emergingindustries.eu). The main objective of this proposal is to provide key solutions for the reconfiguration of the biopharmaceutical value chain in Personalised Medicine towards a Health Economy 4.0, with a special focus on oncology (i.e. cancer treatment). The digitalisation of communication and workflow processes is changing entire value chains. Advancing Personalised Medicine in the digital age requires solutions to issues currently driving the IT and software sector, e.g. Big Data, machine learning, IT security, data protection, and cross-enterprise collaboration. As a cross-cutting industry, the IT and software sector is an innovation enabler in many industries providing process and best practice solutions in diverse industrial and business environments. The project outlined in this proposal will enable further digitalisation of the value chain in Personalised Medicine by applying the knowledge base of the IT industry in an exemplary way, thereby increasing the competitiveness of biopharmaceutical SMEs in Europe.
In a cross-clustering approach, leading biopharma and IT clusters from three countries (Austria, Germany, and Norway) will create novel cross-sectoral collaborations between SMEs to address innovation barriers in the biopharma sector via cutting-edge IT solutions. This will be achieved through an open collaboration space consisting of workshops, a semantic online matchmaking portal, and matchmaking events, allowing biopharma enterprises to identify suitable partners among the IT companies of the participating clusters. In a second step, the biopharmaceutical SME and the IT partner will jointly tackle an innovation barrier in the value chain using an innovation voucher scheme. While finding novel solutions to important innovation barriers in the biopharma sector remains the primary objective of this proposal, a welcome side effect of pairing SMEs from the biopharma and IT sectors would be the entry of participating IT companies into the evolving and highly attractive Digital Health2 sector.
Follow-up coaching by the cluster organisations and transfer activities will maximise business impact and political outreach of the scheme and ensure sustainability of the chosen approach beyond the funding of this proposal.
Key objectives in figures:
- 75 SMEs participating in matchmaking events on regional and European levels
- 100 companies entering their profile into the semantic matchmaking portal
- 90 innovation projects between IT and biopharma companies, supported by innovation vouchers
- 50 sessions of follow-up coaching
- 120 SMEs benefitting from technology transfer activities
Medicine, Biopharma, Biotech, IT and Software sector
The project will develop and test different measures in line with and supported by the Smart Specialisation Strategies of the participating regions, to enable value chain innovation in Personalised Medicine companies through further digitalisation of their processes.
Stage 1 (Months 0-6): Building a joint cross-sectoral and cross-border understanding
In the first stage, cluster-coordinated initiatives will build the foundation for the large-scale demonstrator approach to be pursued by this project. In several stakeholder workshops, cluster members from both the regional biopharma clusters and the IT/software clusters build a common understanding of the status quo of the Personalised Medicine value chain and identify the barriers to innovation. These workshops are carried out on a regional level, and continued on the European level engaging members of all participating clusters. A study and work plan is developed which identifies a) the parts of the value chain that could benefit from a reconfiguration and b) support measures able to drive this change. The Managing Authorities of the local ESIF support measures are involved in the process.
Stage 2 (Months 7-18): Innovation projects
The project’s focus will lie on the design and implementation of concrete innovation support measures to reconfigure the value chain of SMEs in the field of Personalised Medicine. The innovation support includes the following: pooling of companies, establishment of an online platform, conception, preparation and implementation of a continuous open call, selection of SME innovation projects, and finally monitoring and evaluation of sub-grants including allocation of payments. The core element will be an innovation voucher scheme making available different kinds of vouchers to tackle the innovation barriers of the value chain. The innovation vouchers envisaged by this project follow the EC regulations on financial support to third parties as laid out in Annex K of the General Annexes of the Horizon 2020 Work Programme.
Stage 3 (Months 19-24): Follow-up coaching and transfer to other SMEs
In Stage 3 of the project (months 19-24), biopharma SMEs that finished their innovation projects supported by this program will be coached by the cluster organisations regarding further existing support measures, and linked with additional sources of funding from national and regional funds, e.g. those offered by the Managing Authorities of the regional ESIF funded programmes, to maximise the impact of the project. In addition, selected successful innovation projects will be presented via cluster workshops to other SMEs that face similar innovation barriers, thereby transferring key learnings to the clusters at large.
- Strengthening industrial leadership in the EU and Associated Countries
- Stimulate the creation of new globally competitive industrial value chains across the EU and Associated Countries to accelerate the development of emerging industries
- Further leverage and complement support for innovation in SMEs and other funding
- Contribute to regional Smart Specialisation Strategies
- Clear and measurable contribution to the innovation performance of the supported SMEs
- Improve the business environment of the SMEs by establishing open collaboration spaces
Brussels, 05.06.2017 - Two months after the start of the first round of applications the PERMIDES project consortium was able to present a positive picture: the PERMIDES project which is funded by the European Union under the Framework Programme Horizon 2020 has aroused great interest from both the biopharmaceutics and IT branches.
On 10th October 2017, the second deadline for the submission of grant applications for innovation projects came to an end. And the response after the end of the second cut-off day is consistently positive: 73 applications for innovation projects have been submitted of which 51 receive financial funding, each with up to 60,000 Euros. This corresponds to a total funding volume of around 1.55 million Euros for the second application phase In total, including the first application phase, 119 grant applications have been submitted for innovation projects, of which 51 are funded for a total of 2.65 million Euros.
Furthermore, Biopharma SMEs in need of consultancy services could apply for consultancy vouchers, each amounting to a maximum of 5,000 Euros. On 15th November 2017, the opportunity to submit such applications for consultancy vouchers ended: From a total of 91 applications, 41 are now financially supported by consultancy vouchers with a total funding volume of 261,000 Euros.
In total, PERMIDES supports 88 SMEs of the biopharmaceutical sector from 18 European countries. Germany ranks first (24 SMEs), followed by Norway (13) and Austria (12).
More information is available on http://permides.eu/.